Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy
Journal of Hepatocellular Carcinoma · 2026-02 · Volume 13 · 1-17
DOI: 10.2147/jhc.s570962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-02. Verfasst von Hao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Tianjin First Central Hospital, Tianjin, 300384, People's Republic of China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
To develop a nomogram based on clinical characteristics for predicting post-transplant tumor recurrence in hepatocellular carcinoma (HCC) patients beyond the Milan criteria who received transarterial chemoembolization (TACE) bridging therapy.
Methods
A retrospective analysis included 73 such patients (29 conventional TACE [cTACE], 44 drug-eluting bead TACE [DEB-TACE]) who underwent liver transplantation at our institution between January 2013 and January 2020, with follow-up until January 2024 (mean: 33.2 ± 6.5 months). Clinical/pathological features were analyzed via univariate and multivariate Cox regression to identify recurrence-related factors, and a nomogram was constructed. Bootstrap validation (B=20) and receiver operating characteristic (ROC) curves (AUC) evaluated its performance.
Results
The 1-, 2-, 3-year cumulative recurrence rates were 17.8%, 23.3%, 24.7% (median recurrence time: 6 months). cTACE group rates (20.7%, 27.6%, 31.0%) were higher than DEB-TACE (15.9%, 20.5%, 20.5%; P=0.034). Independent risk factors: bridging therapy type (HR=2.402, P=0.034), microvascular invasion (HR=3.445, P=0.001), tumor necrosis rate (HR=26.664, P=0.002), pre-TACE AFP (HR=2.750, P=0.004). The nomogram's AUC for 1-, 2-, 3-year recurrence was 0.740, 0.764, 0.886, with good calibration via bootstrap.
Conclusion
A nomogram based on clinical characteristics accurately predicts post-transplant recurrence in HCC patients beyond the Milan criteria with TACE bridging therapy, providing guidance for optimizing donor allocation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Tianjin First Central Hospital, Tianjin, 300384, People's Republic of China.
Zitieren
APA
Wang, H., Liu, E., Wu, M., Gao, H., Lv, B., Chen, G., & Zeng, X. (2026). Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy. Journal of Hepatocellular Carcinoma, Volume 13, 1-17. https://doi.org/10.2147/jhc.s570962
Vancouver
Wang H, Liu E, Wu M, Gao H, Lv B, Chen G, et al. Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-17. doi:10.2147/jhc.s570962
BibTeX
@article{Wang2026,
author = {Wang, Hao and Liu, Encheng and Wu, Mei and Gao, Haijun and Lv, Bing and Chen, Guang and Zeng, Xunjin},
title = {Development of a Nomogram Model to Predict Post-Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria Undergoing TACE Bridging Therapy},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--17},
doi = {10.2147/jhc.s570962}
}
EUVIMED